Trial Profile
A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Apr 2016
Price :
$35
*
At a glance
- Drugs Rovatirelin (Primary)
- Indications Spinocerebellar degeneration
- Focus Registrational; Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 15 Apr 2016 Status changed from recruiting to completed.
- 04 Nov 2013 New trial record